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Abstract
Reduced plasma levels of HDL-C are associated with an increased risk of CAD
and myocardial infarction, as shown in various prospective population studies.
However, recent clinical trials on lipid-modifying drugs that increase plasma
levels of HDL-C have not shown significant clinical benefit. Notably, in some
recent clinical studies, there is no clear association of higher HDL-C levels with
a reduced risk of cardiovascular events observed in patients with existing CAD.
These observations have prompted researchers to shift from a cholesterol-centric
view of HDL towards assessing the function and composition of HDL particles.
Of importance, experimental and translational studies have further
demonstrated various potential antiatherogenic effects of HDL. HDL has been
proposed to promote macrophage reverse cholesterol transport and to protect
endothelial cell functions by prevention of oxidation of LDL and its adverse
endothelial effects. Furthermore, HDL from healthy subjects can directly stimu-
late endothelial cell production of nitric oxide and exert anti-inflammatory and
antiapoptotic effects. Of note, increasing evidence suggests that the vascular
effects of HDL can be highly heterogeneous and HDL may lose important anti-
atherosclerotic properties and turn dysfunctional in patients with chronic inflam-
matory disorders. A greater understanding of mechanisms of action of HDL and
its altered vascular effects is therefore critical within the context of
HDL-targeted therapies.
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Abbreviations
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
ACS Acute coronary syndrome
apoA-I Apolipoprotein A1
apoA-II Apolipoprotein A2
apoB Apolipoprotein B
apoA-IV Apolipoprotein A-IV
apoC-III Apolipoprotein C-III
apoE Apolipoprotein E
apoJ Apolipoprotein J
Bad Bcl-2-associated death promoter
Bcl-xL B-cell lymphoma-extra large
Bid BH3 interacting domain death agonist
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CAD Coronary artery disease
caspase Cysteine-aspartic proteases
CETP Cholesteryl ester transfer protein
CHF Chronic heart failure
CKD Chronic kidney disease
eNOS Endothelial nitric oxide synthase
HDL High-density lipoprotein
HDL-C High-density lipoprotein cholesterol
HPLC High-performance liquid chromatography
ICAM-1 Intercellular Adhesion Molecule 1
LCAT Lecithin cholesterol acyltransferase
MS/MS Tandem mass spectrometry
LDL Low density lipoprotein
L-NAME L-NG-Nitroarginine Methyl Ester
LOX-1 Lectin-type oxidized LDL receptor 1
LpPLA2 Lipoprotein-associated phospholipase A2
MALDI-TOF-MS Matrix-assisted laser desorption/ionization-time-of-flight mass
spectrometry
MAPK Mitogen-activated protein kinase
MCP Monocyte chemoattractant protein
MDA Malondialdehyde
MI Myocardial infarction
MPO Myeloperoxidase
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells
NO Nitric oxide
oxLDL Oxidized low density lipoprotein
PAF-AH Platelet-activating factor acetylhydrolase
PI3K Phosphoinositide-3-kinase
PLTP Phospholipid transport protein
PON1 Paraoxonase 1
POPC 1-palmitoyl-2-oleoyl-phosphatidylcholine
RCT Reverse cholesterol transport
rHDL Reconstituted high-density lipoprotein
S1P Sphingosine-1-phosphate
SAA Serum amyloid A
SNP Single nucleotide polymorphism
sPLA2-IIa Secretory phospholipase A2-IIa
SR-BI Scavenger receptor type B1
TNF-α Tumor necrosis factor-alpha
VCAM-1 Vascular cell adhesion molecule 1
VLDL Very low density lipoprotein
Dysfunctional HDL: From Structure-Function-Relationships to Biomarkers 339
1 Introduction
It was shown in multiple large prospective studies of cardiovascular risk factors that
reduced plasma levels of HDL-cholesterol (HDL-C) are associated with an
increased risk of coronary artery disease (CAD) (Castelli et al. 1986; Cullen
et al. 1997; Di Angelantonio et al. 2009; Gordon et al. 1977; Sharrett et al. 2001).
Multiple biological functions of HDL have been identified, whereby HDL may
exert antiatherogenic effects (Annema and von Eckardstein 2013; Barter
et al. 2004; Mineo et al. 2006; Rader 2006; Riwanto and Landmesser 2013), e.g.,
HDL from healthy subjects has been shown to directly promote endothelial
antiapoptotic, anti-inflammatory, and antithrombotic effects (Mineo et al. 2006;
Nofer et al. 2004; Rye and Barter 2008; Tall et al. 2008; Yuhanna et al. 2001).
Accordingly, interventions to improve HDL-C levels and/or HDL function are
being intensely evaluated as a potential therapeutic strategy to reduce cardiovascu-
lar risk. However, increasing evidence suggests that the endothelial and vascular
effects of HDL are highly heterogeneous and vasoprotective properties of HDL are
impaired in patients with diabetes, CAD, or chronic kidney dysfunction (Besler
et al. 2011; Khera et al. 2011; Riwanto et al. 2013; Sorrentino et al. 2010).
Intriguingly, several recent clinical trials testing the effects of HDL-C-raising
therapies have failed to demonstrate cardiovascular risk reduction in patients with
CAD. The Investigation of Lipid Level Management to Understand its Impact in
Atherosclerotic Events (ILLUMINATE) trial testing the impact of the CETP
inhibitor torcetrapib on clinical outcome showed increased risk of mortality and
morbidity in patients at high risk for coronary events, despite a substantial increase
of HDL-C levels (Barter et al. 2007). Dalcetrapib, another CETP inhibitor, mod-
estly increased HDL-C levels, but the phase 3 trial dal-OUTCOMES study was
terminated before completion to a lack of efficacy (Schwartz et al. 2012). More
recently, the HPS2-THRIVE trial results showed that adding extended-release
niacin/laropiprant, another HDL-cholesterol-raising agent, to statins did not reduce
the risk of cardiovascular event (Haynes et al. 2013). Taken together, these
observations strongly suggest that plasma HDL-C levels per se are not an optimal
therapeutic target.
Of note, accumulating evidence suggests that the vascular effects of HDL can be
highly heterogeneous and may turn dysfunctional. HDL loses potential anti-
atherosclerotic properties in patients with chronic inflammatory disorders, such as
the antiphospholipid syndrome (Charakida et al. 2009), systemic lupus
erythematosus and rheumatoid arthritis (McMahon et al. 2006), scleroderma
(Weihrauch et al. 2007), metabolic syndrome (de Souza et al. 2008), diabetes
(Persegol et al. 2006; Sorrentino et al. 2010), and CAD (Ansell et al. 2003; Besler
et al. 2011; Riwanto et al. 2013). In a study of 189 patients with chronic kidney
disease on hemodialysis, an impaired anti-inflammatory capacity of HDL was
correlated with a poor clinical outcome (Kalantar-Zadeh et al. 2007). Furthermore,
HDL isolated from subjects with type 1 or type 2 diabetes mellitus or abdominal
obesity had reduced capacity to reverse the inhibition of aortic ring endothelium-
dependent relaxation by oxLDL as compared to HDL from healthy control subjects
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(Persegol et al. 2006, 2007). Importantly, the heterogeneity of the vascular effects
of HDL may be attributed to changes in the HDL-associated proteome and
lipidome, i.e., changes in the amount and type of proteins and lipids bound to the
HDL particle and also posttranslational modifications. In particular, HDL is known
to be susceptible to modification in vitro by a variety of oxidants, such as metal
ions, peroxyl and hydroxyl radicals, aldehydes, various myeloperoxidase (MPO)-
generated oxidants, lipoxygenase, phospholipase A2, elastase, nonenzymatic
glycation, and homocysteinylation (Ferretti et al. 2006). These oxidative
modifications may contribute to the generation of dysfunctional
proinflammatory HDL.
2 HDL and Reverse Cholesterol Transport
2.1 Mechanisms Under Physiological Conditions
One of the antiatherogenic effects of HDL has been attributed to its function in
macrophage reverse cholesterol transport (RCT), i.e., the removal of excess choles-
terol from lipid-laden macrophage foam cells in the atherosclerotic plaque and its
transport to the liver for excretion in the bile (Rader 2006). The first step of
macrophage RCT involves the hydrolysis of cytoplasmic cholesteryl ester into
free cholesterol followed by the efflux of the free cholesterol to mature HDL or
extracellular lipid-poor apoA-I. Macrophage cholesterol efflux is mediated by
active transport systems, which include the ATP-binding cassette transporters
ABCA1 and ABCG1 (Rader 2006; Tall et al. 2008). Studies in macrophages
from ABCA1-knockout or ABCA1-overexpressing mice have shown that
ABCA1 primarily mediates the cholesterol efflux to lipid-poor apoA-I (Bortnick
et al. 2000; Haghpassand et al. 2001). In contrast, ABCG1 largely mediates
cholesterol efflux from macrophages to mature HDL (Tall et al. 2008).
A study by Wang et al. quantitatively assessed the roles of SR-BI, ABCA1, and
ABCG1 in macrophage RCT in mice in vivo (Wang et al. 2007a). Using primary
macrophages lacking SR-BI, the authors demonstrated that SR-BI did not promote
macrophage RCT in vivo after intraperitoneal injection. In contrast, both ABCA1
and ABCG1 contributed to macrophage RCT in vivo. The study also demonstrated
that transplantation of bone marrow from ABCA1/ABCG1-deficient mice
accelerated atherosclerotic lesion formation in LDL receptor-deficient mice
(Wang et al. 2007a). Interestingly, Yvan-Charvet et al. also demonstrated that
SR-BI failed to stimulate net cholesterol efflux from HEK293 cells to plasma
HDL and inhibited ABCG1-mediated cholesterol efflux, which was at least in
part due to the increased uptake of HDL cholesteryl esters into these cells (Yvan-
Charvet et al. 2008).
HDL-associated cholesterol is subsequently esterified by LCAT which transfers
a fatty acyl residue from phospholipids to the 3-beta-hydroxy group of cholesterol.
The final steps of RCT involve the uptake of HDL-C by the liver and its excretion in
the bile. Cholesterol esters and free cholesterol in HDL can either be directly taken
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up by the liver via SR-BI or transferred to apoB containing lipoproteins in a process
mediated by CETP (Cuchel et al. 2009). In the latter pathway, cholesterol esters are
taken up by the liver via the LDL receptor and then hydrolyzed to free cholesterol
which can be excreted directly into the bile or following conversion to bile acid.
2.2 Alterations of the Cholesterol Efflux Capacity of HDL
in Cardiovascular Disease
A case-control study by Khera et al. showed that the cholesterol efflux capacity of
apoB-depleted serum was inversely related to carotid IMT in healthy volunteers
and to the likelihood of angiographic CAD, even after adjustment for HDL-C and
apoA-I levels (Khera et al. 2011). In a separate study, enhanced cholesterol efflux
activity from ABCA1-stimulated macrophages was associated with reduced risk of
prevalent CAD in unadjusted models in two case-control cohorts: an angiographic
cohort comprising stable subjects undergoing elective diagnostic coronary angiog-
raphy and an outpatient cohort (Li et al. 2013). However, the inverse risk relation-
ship remained significant after adjustment for traditional CAD risk factors only
within the outpatient cohort (Li et al. 2013). Surprisingly, higher cholesterol efflux
activity was associated with an increase in prospective 3-year risk of myocardial
infarction/stroke and major adverse cardiovascular events. The authors further
observed that the HDL fraction (1.063< d< 1.21) contained only a minority
(40 %) of [(14)C] cholesterol released, with the majority found within the
lipoprotein particle-depleted fraction, where 60 % was recovered after apoA-I
immunoprecipitation. This is in agreement with previous findings on plasmas from
patients with apoA-I deficiency, such as Tangier disease and LCAT deficiency,
whereby the cholesterol efflux capacity amounted to at least 40 and 20 % of total
and apoB-depleted plasmas from healthy controls, respectively (von Eckardstein
et al. 1995a). However, in these studies the considerable residual cholesterol efflux
capacity of HDL-free or HDL-poor plasma was explained by the abundance of
apoA-I-free HDL particles containing apoA-IV, apoA-II, or apoE rather than by
albumin (Huang et al. 1994, 1995; von Eckardstein et al. 1995a, b).
Importantly, impaired cholesterol efflux capacity of HDL has been associated
with structural changes of the HDL components. Two groups independently
demonstrated that oxidative modification of apoA-I, particularly by oxidation of
methionine, tyrosine, or tryptophan residues through the myeloperoxidase pathway,
dramatically reduced the ability of apoA-I to promote cholesterol efflux through the
ABCA1 pathway (Bergt et al. 2004; Huang et al. 2014; Shao et al. 2006, 2010).
Both groups also demonstrated that apoA-I in patients with cardiovascular disease
was oxidatively modified and defective in promoting cholesterol efflux from
macrophages via ABCA1 (Bergt et al. 2004; Shao et al. 2012; Zheng et al. 2004).
Of note, the cholesterol efflux capacity as determined by the assay protocol of
Khera et al. which is widely used after its prominent publications is potentially
confounded by several HDL-independent factors: the 4-h long incubation with cells
raises the possibility that serum components deregulate the activity of ABCA1 and
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ABCG1. For example, free fatty acids and cytokines are known to alter the
expression of ABCA1 and ABCG1 on both the transcriptional and posttranslational
level. The use of serum instead of plasma implies the activation of thrombin and
other proteases which are known to degrade prebeta-HDL (Eckardstein 2012).
3 Effects of HDL on LDL Oxidation
3.1 Mechanisms Under Physiological Conditions
The antioxidative properties of HDL were first reported by Bowry (Bowry
et al. 1992). It has been suggested that HDL limits the formation of oxidized
LDL (oxLDL) and oxidation of LDL has been proposed for decades to be a key
event in atherogenesis (Heinecke 1998; Witztum and Steinberg 1991). LDL
accumulates in the subendothelial space where it is oxidized by different pathways
such as lipoxygenase, myeloperoxidase, or NADPH oxidase pathways (Diaz
et al. 1997). OxLDL induces the expression of various proinflammatory cytokines,
chemokines, and adhesion molecules (Navab et al. 1996). In addition, it promotes
monocyte chemotaxis, their differentiation into macrophages, and the subsequent
oxLDL uptake that convert them into foam cells, a hallmark of atherosclerotic
plaques (Chisolm et al. 1999).
HDL is a major carrier of lipid oxidation products and specifically apoA-I, the
main protein constituent of HDL, binds to and removes lipid hydroperoxides of
LDL in vitro and in vivo (Navab et al. 2000b). In addition, apoA-I may directly
reduce cholesteryl ester hydroperoxides and phosphatidylcholine hydroperoxides
by oxidation of specific Met residues in the protein (Garner et al. 1998). Interest-
ingly, the resulting oxidized HDL is more rapidly and selectively removed by
hepatocytes than native HDL (Garner et al. 1998). Treatment of human artery
wall cells with apoA-I but not apoA-II, or by addition of native HDL, apoA-I
peptide mimetics, or paraoxonase, prevents the cells from oxidizing LDL in vitro
(Navab et al. 2000a). The antioxidative function of apoA-I was corroborated by the
finding that recombinant HDL containing only apoA-I and 1-palmitoyl-2-oleoyl-
phosphatidylcholine (POPC) was as effective as native HDL in preventing LDL
oxidation. In addition, in vivo studies have demonstrated that apoA-I can act as an
antioxidative, anti-inflammatory, and anti-atherosclerotic agent (Nicholls
et al. 2005a, b; Paszty et al. 1994). This further underlines a key antioxidant role
for the HDL major protein apoA-I (Zerrad-Saadi et al. 2009).
Several other HDL-associated apolipoproteins have also been shown to contrib-
ute to its antioxidant effects. ApoE has been demonstrated to show isoform-
dependent antioxidant activity (Miyata and Smith 1996). ApoE2 stimulates endo-
thelial NO release and exerts anti-inflammatory effects (Sacre et al. 2003). In
contrast, apoE4 has been suggested to be proinflammatory (Ophir et al. 2005).
Another HDL-associated protein, apoA-IV, showed anti-atherosclerotic, anti-
inflammatory, and antioxidant actions in vivo (Ostos et al. 2001; Recalde
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et al. 2004; Vowinkel et al. 2004). In addition, apoJ, also called clusterin, has been
reported to block LDL oxidation by artery wall cells (Navab et al. 1997).
Furthermore, ApoA-II-enriched HDL isolated from transgenic human apoA-II
mice protected VLDL from oxidation more efficiently than control HDL (Boisfer
et al. 2002). In contrast, in other studies, dyslipidemic mice overexpressing human
apoA-II showed accelerated atherosclerosis and reduced antioxidative activity of
HDL, which may be attributed to the displacement of apoA-I and PON1 by apoA-II
in HDL particles (Ribas et al. 2004; Rotllan et al. 2005). Notably, in apparently
healthy subjects from the prospective EPIC-Norfolk (European Prospective Inves-
tigation into Cancer and Nutrition-Norfolk) cohort, apoA-II was found to be
associated with a decreased risk of future CAD in a nested case-control study
(Birjmohun et al. 2007).
Importantly, HDL carries antioxidant enzymes that have the capacity to prevent
lipid oxidation or degrade lipid hydroperoxides such as serum paraoxonase/
arylesterase 1 (PON1), lecithin/cholesterol acyltransferase (LCAT), and platelet-
activating factor acetylhydrolase (PAF-AH). Specifically PON1 has been suggested
to be an important regulator of the potential antiatherogenic capacity of HDL (Shih
et al. 1998; Tward et al. 2002). It is secreted from the liver and associates with HDL
in the plasma. Many studies revealed that PON1 degrades oxidized
proinflammatory lipids, measured as a reduction in lipid peroxides (Mackness
et al. 1991; Shih et al. 2000; Watson et al. 1995). Higher PON1 activity has been
reported to be associated with a lower incidence of major cardiovascular events in
human. Conversely, reduced activity of PON1 has been associated with pathologi-
cal conditions such as diabetes, chronic renal failure rheumatoid arthritis, and
various dementia (Soran et al. 2009).
LCAT is another HDL-associated enzyme with antioxidative properties. The
antioxidant role of LCAT is thought to be its capacity to hydrolyze oxidized acyl
chains from phosphatidylcholine-based oxidized phospholipids and oxidized free
fatty acids (Goyal et al. 1997; Subramanian et al. 1999). Genetics and biochemical
characterizations of HDLs from patients with low HDL disorders demonstrated that
HDL-LCAT activity was reduced in all LCAT mutation carriers as well as in
patients with HDL deficiency due to mutation in APOA1 or ABCA1 (Soran
et al. 2009; von Eckardstein et al. 1995a). In vivo study in mice deficient for
LDL receptor and leptin revealed that LCAT overexpression decreased
autoantibodies to oxLDL (Mertens et al. 2003). Besides LCAT and PON1,
PAF-AH, another HDL-associated enzyme, nowadays also known as lipoprotein-
associated phospholipase A2 (LpPLA2), is able to hydrolyze oxidized
phospholipids (Marathe et al. 2003; Noto et al. 2003). The local expression of
PAF-AH in arteries of non-hyperlipidemic rabbits reduced the accumulation of
oxidatively modified LDL without changing plasma levels of PAF-AH and reduced
the expression of endothelial cell adhesion molecules (Arakawa et al. 2005).
PAF-AH deficiency caused by a missense mutation in the gene has been indicated
to be an independent risk factor for CAD in Japanese men (McIntyre et al. 2009). In
contrast to this both activity and mass concentration of LpPLA2 in total serum has
been associated with increased rather than decreased cardiovascular risk
(Lp et al. 2010). However, recently HDL-associated LpPLA2 was found to be
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inversely related to risk of coronary events in stable CAD patients (Rallidis
et al. 2012). Hence, the lipoprotein distribution of LpPLA2 may determine the
pro- or antiatherogenic role of PAF-AH/LpPLA2. Furthermore, plasma levels of
PAF-AH are also shown to be an independent risk marker of CAD (Garza
et al. 2007). However, a study by Holleboom et al. showed that the reduction in
LCAT and PAF-AH activites due to LCAT mutations was not associated with
increased plasma lipid peroxidation (Holleboom et al. 2012).
3.2 Impairment of the Anti-Oxidative Effects of HDL in Patients
After Surgery and With Cardiovascular Disease
In the acute phase response to surgery, van Lenten et al. demonstrated that the
serum amyloid A (SAA) levels in HDL was increased and the activities of PON1
and PAF-AH were reduced (Van Lenten et al. 1995). Concomitant with these
changes the anti-inflammatory capacity of HDL was lost in both humans and rabbits
(Van Lenten et al. 1995). Isolated HDL from patients before and immediately after
surgery were compared for the effects of HDL on LDL-induced monocyte transmi-
gration and lipid hydroperoxide formation (Van Lenten et al. 1995). Prior to
surgery, HDL completely inhibited the LDL-induced increase in monocyte trans-
migration and lipid hydroperoxide formation. In marked contrast, the “acute phase”
HDL obtained from the same patients 2–3 days after surgery revealed a significant
LDL-induced monocyte transmigration and was less effective in inhibiting lipid
hydroperoxide formation. In other words, HDL in the same patient had been
transformed from anti-inflammatory towards proinflammatory particles (Van
Lenten et al. 1995). Similarly findings were reported in mice infected with influenza
A or Chlamydia pneumonia. HDL isolated from virus-infected wild-type mice had
impaired capacity to block LDL oxidation as well as LDL-induced monocyte
chemotactic activity in human artery wall cell co-cultures (Van Lenten
et al. 2001). The mice infected with C. pneumoniae had decreased PON1 activity
and reduced HDL capacity to prevent LDL oxidation at days 2 and 3 postinfection
(Campbell et al. 2010). Of note, studies by Navab et al. showed that HDL isolated
from patients with CAD failed to prevent LDL oxidation by human artery wall cells
(Navab et al. 2000a) and had impaired capacity to inhibit LDL-induced monocyte
chemotactiy activity (Navab et al. 2001b). Similar results were obtained with HDL
isolated from mice genetically predisposed to diet-induced atherosclerosis; it
became proinflammatory when the mice were fed an atherogenic diet (Navab
et al. 2001a). A subsequent small study by Ansell et al. suggested that the capacity
of HDL to alter LDL-induced monocyte chemotactic activity in patients with CAD
was somewhat improved after 6 weeks of simvastatin therapy (Ansell et al. 2003).
However, HDL from patients with CAD on statin therapy remained
proinflammatory when compared to HDL from healthy subjects, despite a signifi-
cant improvement in plasma lipid levels.
Interestingly, impaired antioxidant properties and increased oxidized fatty acids
content were found in HDL from patients with type 2 diabetes (Morgantini
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et al. 2011). The authors speculated that the elevated levels of oxidized fatty acids
in HDL from these patients may account for the impaired antioxidant properties of
the lipoprotein (Morgantini et al. 2011). Moreover, in a different study, the ability
of HDL to prevent LDL oxidation was found to be reduced in patients with acute
coronary syndrome but not in patients with stable coronary artery syndrome (Patel
et al. 2011). The antioxidative and cholesterol efflux capacities of HDL were also
found to be reduced in ischemic cardiomyopathy (Patel et al. 2013).
4 Effects of HDL on Endothelial Nitric Oxide Bioavailability
4.1 Mechanisms Under Physiological Conditions
Endothelial nitric oxide plays a crucial role in the regulation of vascular tone,
platelet aggregation, and angiogenesis. Endothelial nitric oxide synthase (eNOS)-
derived nitric oxide (NO) has been shown to exert a variety of atheroprotective
effects in the vasculature, such as anti-inflammatory and antithrombotic effects
(Landmesser et al. 2004). Consequently, reduced endothelial NO bioavailability
has been proposed to promote initiation and progression of atherosclerosis
(Landmesser et al. 2004).
It was shown that HDL can directly stimulate eNOS-mediated NO production
(Yuhanna et al. 2001). There have been several studies that consistently
demonstrated the capacity of HDL to modulate eNOS expression and to stimulate
endothelial NO production in vitro and in vivo (Besler et al. 2011; Kuvin
et al. 2002; Mineo et al. 2003; Nofer et al. 2004; Ramet et al. 2003; Sorrentino
et al. 2010). Furthermore, administration of reconstituted HDL (rHDL) has been
shown to improve endothelial function in patients with hypercholesterolemia or in
subjects with isolated low HDL due to heterozygous loss-of-function mutations in
the ABCA1 gene locus (Bisoendial et al. 2003; Spieker et al. 2002). Several
mechanisms have been proposed to account for the endothelial NO-stimulating
capacity of HDL. Early studies have demonstrated that HDL prevents oxLDL-
mediated eNOS displacements from caveolae and restores enzyme stimulation
(Uittenbogaard et al. 2000). Yuhanna et al. demonstrated that HDL binding to
endothelial SR-BI is required for eNOS activation (Yuhanna et al. 2001). This
binding activates the phosphatidylinositol-3-kinase/Akt signaling pathway and the
MAP kinase/extracellular signal-regulated kinase pathway (Mineo et al. 2003).
Activation of endothelial Akt by HDL stimulates phosphorylation of eNOS at
serine residue 1177 (Mineo et al. 2003; Nofer et al. 2004), which is known to be
an important regulatory mechanism leading to eNOS activation (Dimmeler
et al. 1999).
There are many different components of HDL known to play a role in the
endothelial NO-stimulating capacity. The potential interaction of apoA-I with
eNOS in cultured endothelial cells has been previously reported (Ramet
et al. 2003). However, lipid-free apoA-I failed to activate eNOS despite being the
ligand for SR-BI, suggesting that other HDL components may be important or are
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required to support the conformation of apoA-I to allow its interaction with SR-BI
and to stimulate eNOS (de Beer et al. 2001). In isolated endothelial cell plasma
membranes, anti-apoA-I antibody blocks eNOS activation by HDL in vitro
(Yuhanna et al. 2001). In contrast anti-apoA-II antibody further enhances eNOS
stimulation by HDL (Yuhanna et al. 2001). Furthermore, lysophospholipids may
play a role in eNOS activation as demonstrated in several studies. A study by Nofer
et al. suggested that HDL-associated sphingolipids such as sphingosylphosphor-
ylcholine, sphingosine-1-phosphate, and lysosulfatide caused eNOS-dependent
relaxation of precontracted aortic rings from mice by binding to the
lysophospholipid receptor S1P3 expressed in endothelial cells (Nofer et al. 2004).
However, the vasodilatory response of HDL was not completely abolished in S1P3-
deficient mice (Nofer et al. 2004).
Recently, we demonstrated that the HDL-associated enzyme PON1 is
participating in HDL’s capacity to stimulate endothelial NO production and to
exert NO-dependent endothelial atheroprotective effects (Besler et al. 2011). Inhi-
bition of PON1 in HDL from healthy subjects impaired the capacity of HDL to
stimulate endothelial NO production in human aortic endothelial cells. In addition
HDL isolated from PON1-deficient mice failed to stimulate NO production in
mouse aortic endothelial cells (Besler et al. 2011). Furthermore, inhibition of
eNOS-mediated NO production by the pharmacological inhibitor L-NAME
prevented the inhibitory effects of HDL from healthy subjects on nuclear factor
κB (NF-κB) activity, vascular cell adhesion molecule (VCAM)-1 expression, and
endothelial monocyte adhesion. These clearly indicate that the capacity of HDL to
stimulate endothelial NO production is important for these endothelial anti-
inflammatory effects of HDL (Besler et al. 2011).
4.2 Impaired HDL Capacity to Stimulate NO Production in
Patients with Cardiovascular Disease
We and others have recently shown that HDL isolated from patients with stable
CAD, diabetes, chronic kidney diseases (CKD), or acute coronary artery syndrome
(ACS) displays altered endothelial effects when compared to HDL from healthy
subjects. Of note, HDL from patients with diabetes in contrast to HDL from healthy
subjects failed to stimulate endothelial cell NO production and to promote endo-
thelial repair in a carotid artery injury model in mice (Sorrentino et al. 2010).
Moreover, HDL from patients with either stable CAD or an ACS, in contrast to
HDL from age- and gender-matched healthy subjects, inhibited endothelial cell NO
production and lost the capacity to limit endothelial inflammatory activation as well
as to promote endothelial repair in vivo (Besler et al. 2011). Interestingly, the
capacity to stimulate endothelial NO production could be improved upon exercise
training (Adams et al. 2013).
HDL from patients with CAD and chronic heart failure (CHF) showed an
elevated malondialdehyde (MDA) content as compared to HDL from healthy
subjects, which may contribute to the impaired endothelial NO production (Besler
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et al. 2011). The MDA-lysine adducts in HDL was determined to act via lectin-type
oxidized LDL receptor 1 (LOX-1) activation of protein kinase C-βII, which blocks
Akt-activating phosphorylation at Ser473 and eNOS-activating phosphorylation at
Ser1177. Furthermore, inactivation of PON1 in HDL from healthy subjects resulted
in attenuated NO production, in greater protein kinase C-βII activation, decreased
activating eNOS-Ser1177 phosphorylation, and increased inactivating eNOS-
Thr495 phosphorylation. Furthermore, HDL isolated from PON1-deficient mice
failed to stimulate endothelial cell NO production (Besler et al. 2011). These
observations likely suggest that alterations of HDL-associated PON1 may severely
affect endothelial effects of HDL.
Very recently, we have also shown that MPO and PON1 reciprocally modulate
each other’s function in vivo (Huang et al. 2013). MPO may promote site-specific
oxidative modification of PON1, therefore limiting its activity. In addition, HDL
isolated from patients with an ACS carries enhanced chlorotyrosine content, site-
specific PON1 methionine oxidation, and reduced PON1 activity (Huang
et al. 2013).
Several groups have reported an inverse relationship between PON1 serum
activity and cardiovascular events (Bhattacharyya et al. 2008; Regieli
et al. 2009). Interestingly, analysis of SNPs for PON1 identified in genome wide
association studies did not reveal a significant association between SNPs,
associated with mildly reduced PON1 activity, and the risk of cardiovascular events
(Tang et al. 2012). The interpretation of PON1 activity is difficult because it is not
known to which extent the paraoxonase and arylesterase activities represent bio-
logically relevant functions. Furthermore, we and others observed important post-
translational modifications of the proteins, which could explain alterations of
biological properties of the enzymes (Aviram et al. 1999; Besler et al. 2011;
Huang et al. 2013).
5 Endothelial Anti-Inflammatory Effects of HDL
5.1 Mechanisms Under Physiological Conditions
Atherosclerosis is a chronic inflammatory disorder. The cellular inflammatory
response is triggered by modified LDL accumulated in the subendothelium and
the induction of proinflammatory cytokines and adhesion protein expression. As a
consequence monocytes/macrophages infiltrate and accumulate in the arterial wall
and express scavenger receptors and toll-like receptors to sequester cholesterol. The
cholesterol-loaded macrophages together with T lymphocytes produce a wide array
of proinflammatory cytokines and accelerate plague progression (Hansson 2005).
In vitro, HDL has been shown to inhibit the expression of monocyte
chemoattractant protein (MCP)-1, an important proinflammatory chemokine in
endothelial cells (Mackness et al. 2004; Navab et al. 1991). Furthermore, the
potential anti-inflammatory effects of HDL have been demonstrated by several
in vivo studies. Infusion of native HDL as well as reconstituted HDL containing
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apoA-I or apoA-I Milano suppressed cytokine and chemokine expression in animal
models of inflammation (Calabresi et al. 1997; Cockerill et al. 1995). Reduced
VCAM-1 expression and decreased monocyte/macrophage infiltration were
reported after carotid artery cuff injury in apoE-deficient mice (Dimayuga
et al. 1999). In the streptozotocin-induced diabetic cardiomyopathy rat model,
human apoA-I gene transfer increased HDL-C plasma levels and blocked the
diabetes-induced myocardial mRNA expression of VCAM-1 and ICAM-1 (Van
Linthout et al. 2008). In contrast, overexpression of human apoA-I in apoE-
deficient mice did not result in any change of endothelial VCAM-1 expression
and monocyte adherence in early atherosclerotic lesions at the aortic branch sites,
despite overall reduction in aortic atherosclerotic lesion formation (Dansky
et al. 1999). These studies support the concept that the anti-inflammatory capacity
of HDL is heterogeneous, and is dependent on the pathophysiological conditions. In
vitro studies showed variations in the capacity of HDL isolated from different
human subjects to reduce TNF-α stimulated endothelial VCAM-1 expression
(Ashby et al. 1998; Van Lenten et al. 1995). In human studies, the administration
of reconstituted HDL increased the anti-inflammatory capacity of HDL from
patients with type-2 diabetes (Patel et al. 2009).
One of the proposed mechanisms for the anti-inflammatory effect of HDL is the
removal of cholesterol from cell membranes of macrophages and also endothelial
cells. The cholesterol depletion and consequently the lipid rafts disruption may
downregulate signaling pathways and interfere with the antigen presentation or the
expression of toll-like receptor (Anderson et al. 2000; Norata and Catapano 2012;
Wang et al. 2012). Additional studies suggest that HDL and apoA-I are able to
inhibit the capacity of antigen-presenting cells to stimulate T-cell activation. This
inhibition was attributed to cholesterol efflux through ABCA1, an ATP-binding
transporter (Tang et al. 2009; Zhu et al. 2010).
The anti-inflammatory capacity of HDL has been mainly attributed to apoA-I,
the major protein constituent of HDL. In an in vivo study, apoA-I infusion in rabbits
in acute vascular inflammation model reduced neutrophil infiltration and endothe-
lial cell inflammatory activation (Puranik et al. 2008). In addition, apoA-1 mimetic
peptides have been shown to reduce vascular inflammation in type I diabetic rats
and improve insulin sensitivity in obese mice (Peterson et al. 2007, 2008). It has
also been demonstrated that treatment with lipid-free apoA-I and rHDL treatment
reduced the expression of chemokines and chemokine receptors in vitro and in vivo
by modulating NF-κB and peroxisome proliferator-activated receptor γ (Bursill
et al. 2010). Interestingly, apoA-I has also been shown to inhibit palmitate-induced
NF-κB activation by reducing Toll-like receptor-4 recruitment into lipid rafts
(Cheng et al. 2012). More recently, De Nardo et al. using a systems biology
approach identified the transcription factor ATF3 as an HDL-inducible gene to
suppress Toll-like receptor-induced proinflammatory cytokines. Mice deficient in
ATF3 and apoE revealed enhanced atherosclerotic lesions, and administration of
rHDL into apoE-deficient mice resulted in ATF3 upregulation. The authors used
rHDL in their study, suggesting that apoA-I is a key mechanistic player, and of
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note, the effects seem to be unrelated to cholesterol transport (De Nardo
et al. 2014).
The lipid moiety of HDL has also been proposed to be important for the anti-
inflammatory effects of HDL. In vitro studies using reconstituted HDL containing
only apoA-I with a few phospholipid molecules suggested that inhibitory effects of
HDL on endothelial cell adhesion molecule expression are also, at least in part,
dependent on HDL-associated phospholipid species (Baker et al. 2000). The inhi-
bition of cytokine-induced expression of VCAM-1 by reconstituted HDL varied
when different phosphatidylcholine species were used. This suggests that the lipid
composition of HDL influences its anti-inflammatory capacity and is likely an
important determinant of HDL functionality (Baker et al. 2000; Barter
et al. 2004). In addition there are multiple reports suggesting the involvement of
sphingosine-1-phosphate (S1P), a biologically active sphingolipid that plays key
functions in the immune, inflammatory, and cardiovascular systems. S1P carried by
HDL is believed to regulate arterial tone, vascular permeability, and tissue perfu-
sion. During inflammation it induces endothelial adhesion molecules and recruits
inflammatory cells, and furthermore it activates a negative feedback loop that
consecutively decreases vascular leakage by improving the endothelial barrier
function and preventing cytokine-induced leukocyte adhesion (Garcia et al. 2001;
Lucke and Levkau 2010; Takeya et al. 2003).
5.2 Impaired Endothelial Anti-Inflammatory Effects of HDL in
Patients with CAD, Diabetes, or Chronic Kidney Dysfunction
HDL isolated from patients with inflammatory disease such as CAD, diabetes, or
chronic kidney disease display reduced eNOS activation and impaired endothelial
repair capacity in a carotid artery injury mouse model. There have been various
mechanisms proposed to account for the impaired endothelial anti-inflammatory
effects of HDL. Reduced HDL apoA-I levels in inflammatory states has been
related to accelerated HDL catabolism and apoA-I substitution in HDL particles
by serum amyloid A (SAA) (Esteve et al. 2005; Khovidhunkit et al. 2004). In acute
phase, SAA is able to replace apoA-I in HDL, resulting in reduced plasma levels of
apoA-I (Parks and Rudel 1985). ApoA-I can be completely replaced by SAA in
rabbits and mice, in a subset of small, dense HDL particles and therefore function-
ing as a structural apolipoprotein (Cabana et al. 1999). HDL isolated from patients
with chronic kidney disease is enriched in SAA, which correlated with its reduced
anti-inflammatory capacity to inhibit monocyte chemoattractant protein-1 forma-
tion in vascular smooth muscle cells (Tolle et al. 2012).
Moreover, HDL carries potential cardioprotective molecules that are signifi-
cantly altered in compositions in patients with CAD or ACS (Riwanto et al. 2013;
Vaisar et al. 2007). Oxidative modifications of HDL, in particular the amino acid
residues in apoA-I, have been shown to contribute to the generation of dysfunc-
tional HDL (Bergt et al. 2004; Shao et al. 2006, 2012; Zheng et al. 2004). In vitro
study has demonstrated that MPO-catalyzed oxidative modification of HDL or
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apoA-I converts HDL into a proinflammatory particle which promotes NF-κB
activation and endothelial VCAM-1 expression (Undurti et al. 2009). Furthermore,
glycation of HDL and apoA-I, a process that is known to occur in diabetes in vivo
(Curtiss and Witztum 1985), has been shown to impair the anti-inflammatory
capacity of HDL (Nobecourt et al. 2010). Infusion of glycated lipid-free apoA-I
failed to decrease adhesion molecule expression following vascular injury
(Nobecourt et al. 2010). Moreover, glycation of HDL has also been shown to
inhibit the HDL capacity to inhibit oxLDL-induced monocyte adhesion to human
aortic endothelial cells in vitro (Hedrick et al. 2000).
6 Effects of HDL on Endothelial Cell Apoptotic Pathways
6.1 Mechanisms Under Physiological Conditions
Endothelial cell dysfunction and injury has been associated with the pathogenesis
of atherosclerosis (Landmesser et al. 2004; Nabel and Braunwald 2012; Ross 1999).
Studies in pigs have shown that atherosclerotic lesion-prone regions are
characterized by a high endothelial cell turnover (Caplan and Schwartz 1973),
which has been suggested to be due to increased endothelial cell apoptosis (Caplan
and Schwartz 1973). Several studies have indicated an important contribution of
endothelial cell apoptosis to the pathophysiology of CAD (Burke et al. 1997; Rossig
et al. 2001). Furthermore, it is evident that apoptosis of endothelial cells and smooth
muscle cells is detrimental to plaque stability (Bombeli et al. 1997; Kockx and
Herman 2000). In the normal arterial wall, endothelial cells may protect themselves
against apoptosis using NO-dependent mechanisms. The situation is completely
different in atherosclerotic plaques, in a high oxidative stress environment where
macrophages produce high amounts of nitric oxide or peroxynitrite that could
induce apoptotic cell death (Kockx and Herman 2000). In the aorta the capacity
of HDL to quench endothelial cell apoptosis may therefore represent an
antiatherogenic property of HDL (de Souza et al. 2010; Nofer et al. 2001; Suc
et al. 1997; Sugano et al. 2000).
HDL has been shown to attenuate endothelial cell apoptosis induced by different
stimuli such as TNF-α, oxLDL, and growth factor deprivation (de Souza et al. 2010;
Nofer et al. 2001; Suc et al. 1997; Sugano et al. 2000). It has been suggested that
HDL may inhibit both death-receptor and mitochondrial-mediated apoptotic
pathways. Importantly, both the protein and lipid moieties have been reported to
contribute to the antiapoptotic capacity of HDL. ApoA-I has been shown to inhibit
endothelial cell apoptosis induced by oxLDL, VLDL, and TNF-α (Speidel
et al. 1990; Suc et al. 1997; Sugano et al. 2000). In a more detailed study, HDL
subpopulations enriched with apoA-I account for approximately 70 % of the
antiapoptotic activity of HDL in a cell culture model with human microvascular
endothelial cells that were treated with mildly oxidized LDL. Using rHDL
consisting of apoA-I, cholesterol and phospholipids potently inhibited oxLDL-
induced apoptosis in these cells (de Souza et al. 2010). This suggests that apoA-I
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plays an important role for the antiapoptotic capacity of HDL in oxLDL-stimulated
endothelial cells.
HDL-associated lysosphingolipids have been identified to inhibit endothelial
cell apoptosis induced by growth factor deprivation (Kimura et al. 2001, 2003;
Nofer et al. 2001). The antiapoptotic capacity of the lipid moiety of HDL was
further supported by the findings that the ratio of sphingosine-1-phosphate and
sphingomyelin in small dense HDL3 particles was increased and correlated posi-
tively with the characteristics of these HDL subpopulations to inhibit endothelial
cell apoptosis (Kontush et al. 2007).
Several mechanisms have been suggested for the endothelial antiapoptotic
effects of HDL, depending on the stimulus of apoptosis. Endothelial cell death
triggered by oxLDL causes a delayed but sustained increase in intracellular calcium
which is shown to be prevented by HDL (Suc et al. 1997). HDL inhibits tumor
necrosis factor-α-induced endothelial cell death by association as well as suppres-
sion of caspase-3, which is a key factor of all primary apoptotic pathways (Sugano
et al. 2000). Nofer et al. suggested that sphingosine-1-phosphate (S1P) carried by
HDL prevents the growth factor deprived activation of the intrinsic pathway to cell
death (Nofer et al. 2001). Of note, lysophospholipids have been shown to enhance
endothelial cell survival, but the effects were inhibited by S1P receptor knockdown,
as well as by the presence of phosphoinositide 3 (PI3) kinase and Erk pathway
antagonists (Kimura et al. 2003).
In addition, HDL activates Akt and causes phosphorylation of the Akt target
Bcl-2-associated death promoter (BAD), preventing it from binding to the
antiapoptotic protein Bcl-xL (Nofer et al. 2001). HDL also causes phosphoinositide
3 (PI3) kinase-mediated upregulation of the antiapoptotic Bcl-2 family protein
Bcl-xL expression (Riwanto et al. 2013). Interestingly, HDL retained its
antiapoptotic activity after knockdown of eNOS using specific RNA interference
or pharmacological inhibition using L-NAME (Riwanto et al. 2013), indicating that
HDL may exert its antiapoptotic activity independently of eNOS activation.
6.2 Impairment of the Endothelial Anti-Apoptotic Effects of HDL
in Patients with Cardiovascular Disease
Recently, we reported that HDL isolated from patients with stable CAD or ACS, in
contrast to HDL from healthy subjects, failed to inhibit endothelial cell apoptosis
in vitro and in apoE-deficient-mice in vivo. Using proteomic analysis of HDL, we
observed reduced clusterin and increased apo C-III content in HDL isolated from
patients with CAD. Both, supplementing HDL from healthy subjects with apoC-III
or pretreatment of healthy HDL with an antibody against clusterin, lead to the
activation of proapoptotic signaling pathways in endothelial cells (Riwanto
et al. 2013). HDL isolated from these patients stimulated endothelial proapoptotic
pathways, in particular p38-MAPK-mediated activation of the proapoptotic Bcl-2-
protein tBid. Our study further suggests that differences in the proteome of HDL
from patients with CAD, in particular reduced HDL-associated clusterin and
increased HDL-associated apoC-III, play an important role for altered activation
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of endothelial anti- and proapoptotic signaling pathways (Riwanto et al. 2013). In
line with this, a nested case-control study found that cholesterol levels in apoC-III-
containing HDL particles show a positive association with cardiovascular risk,
whereas both total HDL-C and cholesterol in apoC-III-free HDL particles show
the expected inverse associations (Jensen et al. 2012). In addition, Undurti
et al. demonstrated that MPO-catalyzed oxidation of HDL impaired its capacity
to inhibit endothelial apoptosis in vitro (Undurti et al. 2009).
7 HDL Protein Cargo and Prognostic Biomarkers
As highlighted above, alterations in HDL functions are likely, at least in part,
attributed to changes in the composition of HDL particles. HDL particles are highly
heterogenous in their structure and compositions. They undergo continuous
remodeling through apolipoprotein exchanges with other circulating lipoproteins
and tissues (Lund-Katz et al. 2003; Saito et al. 2004).
An early study has shown that acute phase response causes significant changes in
the HDL-associated proteins and apolipoprotein composition, i.e., enrichment in
C-reactive protein (CRP), secretory phospholipase A2-IIa (sPLA2-IIa), serum amy-
loid A (SAA), and cholesterol ester transfer protein (CETP) (Coetzee et al. 1986). It
has been suggested that such remodeling may compromise the antiatherogenic
functions of HDL (Jahangiri et al. 2009). These observations have prompted
explorative studies into HDL composition. Evaluations of the HDL proteome
have been reported with one- or two-dimensional electrophoresis combined with
high performance liquid chromatography (HPLC) and tandem mass spectrometry
(MS/MS) or matrix-assisted laser desorption/ionization-time flight mass spectrom-
etry (MALDI-TOF-MS) (Heller et al. 2007; Karlsson et al. 2005). More recent
studies have used shotgun proteomics, through label-free MS techniques, such as
spectral counting and XIC inspection, to analyze HDL protein compositions
(Riwanto et al. 2013; Vaisar et al. 2007). Overall, the identification techniques
currently available for the analysis of the HDL proteome are semi-quantitative.
Given the complexity of HDL and its multitude of biological functions, it is
conceivable to expect that sets of functionally associated proteins can provide
information about their participation in the spectrum of atheroprotective actions
attributed to HDL. This has further led to studies comparing the HDL proteome of
healthy subjects with that of particles from patients with dyslipidemias or CAD
(Green et al. 2008; Heller et al. 2007; Riwanto et al. 2013; Vaisar et al. 2007). In the
study by Vaisar et al., HDL was shown to carry apolipoproteins and proteins with
functions in lipid metabolism, the acute phase response, complement regulation,
and blood coagulation (Vaisar et al. 2007). The same group further compared the
proteome of HDL3 from 6 CAD patients before and after 1-year treatment with
combined statin/niacin therapy (Green et al. 2008). In this study, HDL3 of CAD
patients is significantly enriched in apoE and apoCII and carry less apoJ and
phospholipid transport protein (PLTP) as compared to HDL from control subjects.
Treatment with niacin/statin decreases HDL3 apoE and raises apoJ and PLTP levels
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(Green et al. 2008). In our recent study, we have observed that reduced clusterin and
increased apoC-III content in HDL isolated from patients with CAD lead to
activation of proapoptotic signaling pathways in endothelial cells (Riwanto
et al. 2013).
Of note, oxidative modifications of HDL-associated proteins have also been
demonstrated to contribute to the functional impairment of HDL. In particular,
MPO-mediated oxidation of apoA-I has been linked to the generation of dysfunc-
tional forms of HDL (Huang et al. 2014; Shao et al. 2010; Undurti et al. 2009; Wang
et al. 2007b; Zheng et al. 2004). Recently, we have shown that MPO and PON1
interact and reciprocally modulate each other’s function in vivo, i.e., PON1 par-
tially inhibits MPO activity, while MPO oxidizes and inactivates PON1 (Huang
et al. 2013). Furthermore, HDL isolated from patients with an ACS carries
enhanced chlorotyrosine content, site-specific PON1 methionine oxidation, and
reduced PON1 activity (Huang et al. 2013).
Taken together, these observations indicate that the HDL proteomic composition
may be altered in different disease states which likely have an impact on HDL
function. Unraveling the complexities of the HDL through proteomics studies may
therefore allow for better understanding of the HDL composition and function.
However, proteomics studies of HDL have been limited in size and number due to
the labor-intensive nature of the approach. Furthermore, given the diverse concen-
tration range of the proteins in the HDL particles, some proteomics approaches may
fail to reflect the actual amount or alteration of low abundant proteins due to signal
suppression in the presence of highly abundant proteins. Targeted proteomics using
selected reaction monitoring is a powerful tandem mass spectrometry method that
can be used to monitor target peptides within a complex protein digest (Picotti and
Aebersold 2012; Picotti et al. 2010). The approach will enable absolute quantifica-
tion of the individual protein contained within HDL particles.
Conclusion and Perspectives
Over the past two decades, many studies have emerged showing various
antiatherogenic effects of HDL, including the capacity of HDL to mediate
reverse cholesterol transport, and antioxidative, anti-inflammatory, and
antiapoptotic effects (Riwanto and Landmesser 2013). Growing evidence has
shown that HDL particles are highly heterogeneous and the vasoprotective
effects of HDL are altered in patients with CAD, diabetes, and chronic kidney
dysfunction, i.e., patients with a high cardiovascular risk profile. Of note, these
findings have more recently been supported by observations in cohort studies,
suggesting that in patients with advanced CAD, higher plasma levels of HDL-C
are no longer associated with reduced risk of cardiovascular events (Angeloni
et al. 2013; Schwartz et al. 2012). Importantly, the increase in HDL-C observed
with some lipid-modifying drugs has not been uniformly associated with clinical
benefit (Barter et al. 2007; Schwartz et al. 2012). These findings have clearly
indicated that the association between HDL and cardiovascular disease is far
more complex than previously thought and is likely mediated by different HDL
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functional properties, independent of the cholesterol component of the HDL
particle (Heinecke 2011).
It is increasingly evident that the functional heterogeneity of HDL may be
attributed to the complexity of the HDL particles, containing proteins and lipids
that can be modified or altered in their composition. Of note, rapid advances in
the MS proteome technology have allowed tremendous leaps in characterizing
the HDL proteome. Studies investigating the lipidome of HDL are still some-
what limited by the available technologies. Importantly, several studies have
associated changes in specific HDL protein either due to altered composition or
modification to the loss of function of HDL (Besler et al. 2011; Huang
et al. 2013; Riwanto et al. 2013; Shao et al. 2006, 2012; Zheng et al. 2004).
Nevertheless, it remains to be determined if the alterations are secondary to
changes that occur during the disease progression or if the alteration has indeed a
causal effect on disease etiology. In this context it is also important to emphasize
the problem of confounding between different diseases: for example, many
diabetic patients have (sub)clinical chronic kidney disease and/or CAD. As a
consequence one must also expect considerable overlap of HDL modifications
which were initially identified in patients with either diabetes, CAD, or CKD. It
is hence rather unlikely that each disease has its specific footprint of HDL
dysfunction and alterations in proteome and lipidome.
Taken together, it is becoming clear that plasma HDL-C levels are not an
appropriate marker of vascular effects of high-density lipoproteins and therefore
do not represent a reliable therapeutic target. Importantly, HDL-targeted treat-
ment approaches need to take into account the altered vascular effects of HDL in
cardiovascular disease. Therefore, targeting HDL-mediated antiatherogenic
mechanisms, rather than plasma HDL-C levels, may represent a more promising
and interesting therapeutic target. Studies looking into the specific mechanisms
leading to a loss of antiatherogenic effects of HDL are of particular importance,
in order to develop therapeutic approaches that aim to restore the vasoprotective
properties of HDL.
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